Moderna’s much-anticipated combination respiratory vaccine—mRNA-1083—was once expected to be a cornerstone of post-pandemic immunization strategy. Designed to simplify protection against COVID-19, seasonal influenza, and ultimately RSV, the single-dose shot promised greater compliance, better convenience, and platform efficiency. But as of mid-2025, the biotech firm is facing regulatory friction, mounting financial pressure, and delayed commercialization timelines.
The American mRNA developer voluntarily withdrew its Biologics License Application (BLA) for mRNA-1083 in May 2025, after the U.S. Food and Drug Administration (FDA) indicated that more robust flu efficacy data would be needed to support approval. While the company expects to resubmit its application by the end of 2025, the earliest commercial rollout now appears pushed to 2026—a year later than initially hoped.
The setback arrives at a crucial moment for Moderna, which is working to diversify its portfolio beyond COVID-19 vaccines and reassure investors that its mRNA platform can power long-term growth in the infectious disease space.
Why did Moderna withdraw the mRNA-1083 application and delay its combo vaccine timeline?
Moderna’s decision to withdraw its application for mRNA-1083 was a pre-emptive move, prompted by regulatory feedback that the submission lacked sufficient data demonstrating the flu component’s effectiveness. While early results had shown promising immunogenicity—meaning the shot produced strong antibody responses—the FDA has taken a firmer stance on requiring real-world efficacy evidence for combination vaccines.
Specifically, regulators are asking for placebo-controlled trial data that shows mRNA-1083 can reduce confirmed illness and hospitalization, not just raise antibody levels. As a result, Moderna has paused its filing and is now waiting for final Phase III efficacy data from its standalone flu vaccine candidate, mRNA-1010, to form the basis of a stronger combo submission.
Company executives stated that the resubmission is now scheduled for late 2025, effectively pushing the market launch of mRNA-1083 into calendar year 2026.
What do the latest clinical results from Moderna’s flu vaccine candidate mRNA-1010 reveal?
The good news for Moderna is that its standalone mRNA-based flu vaccine, mRNA-1010, has delivered the kind of efficacy data that regulators were looking for. In a Phase III trial involving adults aged 50 and older, mRNA-1010 demonstrated a 26.6 percent higher vaccine efficacy compared to a licensed, non-mRNA flu shot. Among participants aged 65 and older, the efficacy edge widened slightly to 27.4 percent.
These results were statistically significant and marked the first time that Moderna’s flu vaccine candidate had clearly outperformed a traditional comparator. The positive data from mRNA-1010 is expected to strengthen Moderna’s regulatory position when it resubmits the mRNA-1083 application later this year. The company is now aligning its combo vaccine strategy closely with the proven performance of mRNA-1010.
How effective is Moderna’s combo COVID–flu vaccine based on early clinical studies?
Although direct efficacy data is still pending, Moderna has released early immunogenicity data from an 8,000-participant study that shows the mRNA-1083 combo vaccine produces stronger immune responses than separate flu and COVID-19 shots administered in series. The combination formulation reportedly generated robust neutralizing antibody responses against both influenza strains and SARS-CoV-2, particularly in older adults.
In a peer-reviewed study published in the Journal of the American Medical Association, participants aged 50 and older who received the combo shot showed greater seroconversion rates compared to those who received separate shots. This points to the potential of mRNA-1083 to simplify seasonal immunization without compromising immune protection.
However, the FDA has made it clear that immunogenicity alone is not enough for licensure. The agency wants to see clinical evidence that the shot actually reduces flu and COVID-19 cases and complications in the population, especially among older and high-risk adults. That level of data is expected to be available only after the mRNA-1010 trials are fully completed and peer-reviewed.
How do these delays affect Moderna’s broader respiratory vaccine portfolio and revenue outlook?
The delay in bringing mRNA-1083 to market comes as Moderna is facing increasing scrutiny over its ability to commercialize products beyond its flagship COVID-19 vaccine. In the first quarter of 2025, the company posted an adjusted loss of $2.52 per share, missing Wall Street expectations and reflecting a steep decline in COVID-19-related revenue. The biotech firm has already warned investors that combo vaccine approvals may not occur until 2026 at the earliest.
At the same time, Moderna’s RSV vaccine, marketed as mRESVIA, is expected to enter a highly competitive market that already includes approved products from Pfizer and GSK. Without a combination shot ready for the 2025–2026 season, Moderna risks ceding ground to competitors who are also working on multivalent formulations for respiratory syncytial virus, COVID-19, and flu.
Analysts have expressed concern that Moderna may burn through its cash reserves if its pipeline continues to encounter regulatory setbacks. With only a few years of pandemic profits remaining on the balance sheet, investor pressure is mounting for the company to deliver on its pipeline promises—particularly in respiratory vaccines, where the commercial opportunity is considered one of the largest.
How does Moderna’s strategy compare with Pfizer and other vaccine developers in the combination space?
Pfizer is also developing combination vaccine candidates but has taken a more segmented approach to commercialization. The pharmaceutical giant has focused on updating its COVID-19 vaccine formulations, such as the newly approved COMIRNATY LP.8.1 for the 2025–2026 respiratory season, while continuing parallel trials for combination shots.
Unlike Moderna, Pfizer has not withdrawn its applications and has maintained a steady cadence of submissions based on available efficacy data. That said, Pfizer has not yet secured regulatory approval for any combination shot involving COVID-19 and flu or RSV. Both companies are navigating a landscape where the FDA is tightening standards around real-world effectiveness, especially in light of public scrutiny surrounding vaccine rollouts.
Other players in the mRNA and respiratory vaccine space—including Sanofi, Novavax, and GSK—are exploring protein-based or adjuvanted combination approaches. Moderna remains the only biotech currently pursuing a full mRNA platform for triple-virus protection, though its timeline is now lagging behind initial forecasts.
What is the likelihood of a successful resubmission and 2026 launch for mRNA-1083?
The probability of approval in 2026 hinges on several factors. First, the upcoming Phase III readouts for mRNA-1010 must continue to show strong efficacy and safety results. Second, the FDA must be satisfied with the trial design, endpoints, and clinical population used in the combined shot data. Third, Moderna must maintain manufacturing readiness to produce and distribute the vaccine at scale.
While the biotech firm remains confident in the underlying science and market demand for a simplified immunization solution, the regulatory pathway has proven more rigorous than expected. If Moderna can align its data package with FDA expectations and resubmit on schedule in late 2025, a 2026 approval and launch remains within reach.
However, any further setbacks—such as efficacy shortfalls, manufacturing issues, or changes in viral circulation—could push the timeline back again. For now, institutional sentiment around Moderna’s combo vaccine has shifted from exuberant to cautious optimism.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
